Navigation Menu

Clinical Trial External Search

Children (age < 18 years)
Adults (age >= 18 years)

Researcher Profile

Researcher Display

Andrea Manni, MD

Andrea Manni, MD

Professor, Department of Medicine
Chief, Division of Endocrinology and Diabetes
Scientific Program:Cancer Control

Research Interests

Dr. Andrea Manni joined the faculty of Penn State College of Medicine in 1982 and has more than 200 scholarly publications. His primary research interest has been breast cancer with a focus on endocrine determinants of tumor biology, autocrine/paracrine factors mediating hormonal effects and interactions between hormones and polyamines in tumor control.

Dr. Manni’s research teams were among the first to demonstrate the potent antitumor activity of the antiestrogen Tamoxifen in women with hormone-responsive breast cancer. Recently, he has focused on breast cancer prevention through dietary manipulations with omega-3 fatty acids (n-3FA) in conjunction with antiestrogens. His most recent work has indicated that among n-3FA, docosahexaenoic acid (DHA) may be the most potent in selectively reducing breast cancer risk in obese postmenopausal women. He has lectured extensively on this topic nationally and internationally.

Throughout his career, Dr. Manni has served on research grant review committees such as NIH and Department of Defense study sections. He has been an editor of the Journal of Clinical Endocrinology and Metabolism, the premiere clinical journal of the Endocrine Society. He has also been on the editorial boards of several journals with a focus on endocrine oncology.

  • Breast Neoplasms
  • Neoplasms
  • Polyamines
  • Therapeutics
  • Growth
  • Hormones
  • Tamoxifen
  • Eflornithine
  • Estrogens
  • Estrogen Receptor Modulators
  • Prolactin
  • Methylnitrosourea

Recent Publications


Manni, A, Sun, YW, Schell, TD, Lutsiv, T, Thompson, H, Chen, KM, Aliaga, C, Zhu, J & El-Bayoumy, K 2023, 'Complementarity between Microbiome and Immunity May Account for the Potentiating Effect of Quercetin on the Antitumor Action of Cyclophosphamide in a Triple-Negative Breast Cancer Model', Pharmaceuticals, vol. 16, no. 10, 1422.
Manni, A & El-Bayoumy, K 2023, 'Lifestyle Modifications and Breast Cancer Risk', Cancers, vol. 15, no. 11, 2870.


Lorenz, FJ, Beauchamp-Perez, F, Manni, A, Chung, T, Goldenberg, D & Goyal, N 2022, 'Analysis of Time to Diagnosis and Outcomes among Adults with Primary Hyperparathyroidism', JAMA network open, vol. 5, no. 12, pp. E2248332.
Thompson, HJ, Neil, ES, McGinley, JN, Fitzgerald, VK, El Bayoumy, K & Manni, A 2022, 'Building a foundation for precision onco-nutrition: Docosahexaenoic acid and breast cancer', Cancers, vol. 14, no. 1, 157.


Chen, KM, Thompson, H, Vanden-Heuvel, JP, Sun, YW, Trushin, N, Aliaga, C, Gowda, K, Amin, S, Stanley, B, Manni, A & El-Bayoumy, K 2021, 'Lipoxygenase catalyzed metabolites derived from docosahexaenoic acid are promising antitumor agents against breast cancer', Scientific reports, vol. 11, no. 1, 410.


Li, Y, Fan, CY, Manni, A & Simonds, WF 2020, 'Pitfalls of using denosumab preoperatively to treat refractory severe hypercalcaemia', BMJ case reports, vol. 13, no. 4, 233665.